Alamar Biosciences, Inc., a prominent leader in precision proteomics focused on early disease detection, has officially launched the NULISAseq Neuro 220 Panel. This innovative panel represents the company's largest and most advanced precision proteomics tool, designed to significantly enhance research into neurological diseases with its exceptional sensitivity and specificity.
Expanding Coverage for Neurodegenerative Diseases
The NULISAseq Neuro 220 Panel builds upon the success of the flagship NULISAseq CNS Disease Panel 120, offering multiplexed measurement of 220 biomarkers from a single sample. This expansion includes 15 new biomarkers developed with support from The Michael J. Fox Foundation for Parkinson's Research (MJFF), along with 12 assays specifically targeting brain and peripheral Tau isoforms. The panel covers key hallmarks of neurodegenerative diseases, making it a powerful resource for studying conditions like Alzheimer's and Parkinson's.
Enhanced Tau Protein Analysis
A standout feature of the panel is its comprehensive suite of Tau assays, which includes highly selective tests for total tau and phosphorylated species such as pTau217, pTau181, pTau205, pTau212, and pTau231. This collection is believed to be the largest available in a single panel, showcasing the NULISA chemistry's ability to distinguish between organ-specific isoforms and various post-translational modifications.
Support from The Michael J. Fox Foundation
Dr. Nicole Polinski, Director of Research Programs at MJFF, expressed pride in supporting Alamar's efforts. "We are proud to support Alamar as they work to develop highly sensitive assays for several known and emerging biomarkers important in Parkinson's disease research," she said. "We believe these assays will help the research community to better understand disease progression and expedite the development of diagnostic and prognostic signatures."
Leadership Insights
Dr. Yuling Luo, founder, chairman, and CEO of Alamar, highlighted the panel's role in advancing precision proteomics. "This launch reflects our continued innovation in precision proteomics, expanding our neurodegenerative disease panel to better capture the molecular complexity of diseases such as Alzheimer's and Parkinson's," he stated. "We're grateful for The Michael J. Fox Foundation's trust and partnership, and for their collaboration in advancing Parkinson's novel biomarker content for the research community."
Broad Applications and Technological Advantages
The NULISAseq Neuro 220 Panel sets a new standard for neurodegenerative disease research, with applications across a wide range of neurological disorders, including:
- Alzheimer's disease
- Parkinson's disease
- Multiple sclerosis
- Frontotemporal dementia
- Lewy body dementia
- Progressive supranuclear palsy
- Amyotrophic lateral sclerosis
- Huntington's disease
- Vascular dementia
- Gliomas
- Traumatic brain injury
The panel's ultra-high sensitivity and high specificity ensure compatibility with non-invasive sample collection devices, supporting pre-symptomatic detection. Automated workflows using the ARGO HT System deliver exceptional reproducibility and ease of use, facilitating the analysis of disease heterogeneity, detection of co-pathologies, and identification of prognostic or therapeutic response signatures across clinical cohorts.
Upcoming Presentations
Data from the NULISA platform will be featured in over 11 scientific sessions and 25 posters at the International Conference on Alzheimer's & Parkinson's Diseases (AD/PD 2026), underscoring its significance in the field. This launch marks a pivotal step forward in the quest to understand and combat neurological diseases through advanced proteomic technology.
